IL167848A - Use of brimonidine in the manufacture of a medicament for treating neurodegenerative conditions - Google Patents
Use of brimonidine in the manufacture of a medicament for treating neurodegenerative conditionsInfo
- Publication number
- IL167848A IL167848A IL167848A IL16784805A IL167848A IL 167848 A IL167848 A IL 167848A IL 167848 A IL167848 A IL 167848A IL 16784805 A IL16784805 A IL 16784805A IL 167848 A IL167848 A IL 167848A
- Authority
- IL
- Israel
- Prior art keywords
- brimonidine
- medicament
- manufacture
- treating neurodegenerative
- neurodegenerative conditions
- Prior art date
Links
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 title 1
- 229960003679 brimonidine Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 230000000626 neurodegenerative effect Effects 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000000979 retarding effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41703102P | 2002-10-08 | 2002-10-08 | |
| PCT/US2003/031842 WO2004032934A1 (en) | 2002-10-08 | 2003-10-07 | Method of using (2-imidazolin-2-ylamino) qinoxalines in the treatment of dementia and parkinsons |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL167848A true IL167848A (en) | 2010-11-30 |
Family
ID=32093952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL167848A IL167848A (en) | 2002-10-08 | 2005-04-04 | Use of brimonidine in the manufacture of a medicament for treating neurodegenerative conditions |
Country Status (20)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7512436B2 (en) * | 2004-02-12 | 2009-03-31 | The Regents Of The University Of Michigan | Method of evaluating metabolism of the eye |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US20100298305A1 (en) * | 2008-11-26 | 2010-11-25 | The United States Government, As Represented By The Department Of Veterans Affairs | Tizanidine for the treatment of post-traumatic stress disorder and nightmares |
| DE102009043750A1 (de) * | 2009-09-30 | 2011-08-04 | Carl Zeiss Meditec AG, 07745 | Verfahren und Vorrichtung zur Detektion von Ablagerungen im Auge |
| US10022341B2 (en) * | 2014-12-02 | 2018-07-17 | Yale University | Methods of preventing neurodegeneration of association cortex in a mammal |
| RU2680526C1 (ru) * | 2016-07-05 | 2019-02-22 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Нейропротекторное средство, обладающее свойствами антиоксиданта и донатора оксида азота |
| JP2019526055A (ja) * | 2016-08-01 | 2019-09-12 | コグノプティックス， インコーポレイテッド | 眼組織におけるタウタンパク質を検出するためのシステムおよび方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4029792A (en) * | 1972-02-29 | 1977-06-14 | Pfizer Inc. | (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents |
| BE795970A (fr) * | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
| US5210076A (en) * | 1988-09-13 | 1993-05-11 | Berliner David L | Methods of treating Parkinson's disease using melanin |
| DK0828513T3 (da) * | 1995-05-26 | 2004-04-13 | Pfizer | Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister |
| US6194415B1 (en) * | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| US6841684B2 (en) * | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| US6329369B1 (en) * | 1997-12-04 | 2001-12-11 | Allergan Sales, Inc. | Methods of treating pain and other conditions |
| PT1036065E (pt) * | 1997-12-04 | 2004-09-30 | Allergan Inc | Derivados de imidazol substituidos com actividade do tipo agonista nos receptores alfa 2b ou 2b/2c adrenergicos |
| US6313172B1 (en) * | 2000-04-13 | 2001-11-06 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
| EP1365811A2 (en) * | 2000-07-14 | 2003-12-03 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
-
2003
- 2003-10-07 JP JP2004543508A patent/JP2006504741A/ja active Pending
- 2003-10-07 US US10/680,996 patent/US20040116436A1/en not_active Abandoned
- 2003-10-07 HK HK06100172.4A patent/HK1080408B/en not_active IP Right Cessation
- 2003-10-07 DE DE60318081T patent/DE60318081T2/de not_active Expired - Lifetime
- 2003-10-07 RU RU2005114505/14A patent/RU2332218C2/ru not_active IP Right Cessation
- 2003-10-07 EP EP03773199A patent/EP1549314B1/en not_active Expired - Lifetime
- 2003-10-07 KR KR1020057006115A patent/KR20050056235A/ko not_active Ceased
- 2003-10-07 BR BR0314541-7A patent/BR0314541A/pt not_active IP Right Cessation
- 2003-10-07 CA CA002501348A patent/CA2501348A1/en not_active Abandoned
- 2003-10-07 ES ES03773199T patent/ES2297233T3/es not_active Expired - Lifetime
- 2003-10-07 AU AU2003279874A patent/AU2003279874A1/en not_active Abandoned
- 2003-10-07 MX MXPA05003665A patent/MXPA05003665A/es active IP Right Grant
- 2003-10-07 WO PCT/US2003/031842 patent/WO2004032934A1/en not_active Ceased
- 2003-10-07 AT AT03773199T patent/ATE380551T1/de not_active IP Right Cessation
- 2003-10-07 NZ NZ539329A patent/NZ539329A/en not_active IP Right Cessation
- 2003-10-07 CN CNB2003801011164A patent/CN100370988C/zh not_active Expired - Fee Related
- 2003-10-07 PL PL03376347A patent/PL376347A1/xx not_active Application Discontinuation
-
2005
- 2005-04-04 NO NO20051664A patent/NO20051664L/no not_active Application Discontinuation
- 2005-04-04 IL IL167848A patent/IL167848A/en not_active IP Right Cessation
- 2005-04-05 ZA ZA200502745A patent/ZA200502745B/en unknown
-
2010
- 2010-02-26 AU AU2010200730A patent/AU2010200730A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2005114505A (ru) | 2005-10-27 |
| ATE380551T1 (de) | 2007-12-15 |
| NZ539329A (en) | 2007-11-30 |
| EP1549314B1 (en) | 2007-12-12 |
| CN100370988C (zh) | 2008-02-27 |
| ZA200502745B (en) | 2006-07-26 |
| WO2004032934A1 (en) | 2004-04-22 |
| ES2297233T3 (es) | 2008-05-01 |
| PL376347A1 (en) | 2005-12-27 |
| CN1703222A (zh) | 2005-11-30 |
| US20040116436A1 (en) | 2004-06-17 |
| AU2003279874A1 (en) | 2004-05-04 |
| MXPA05003665A (es) | 2005-06-08 |
| HK1080408B (en) | 2008-08-08 |
| DE60318081D1 (de) | 2008-01-24 |
| AU2010200730A1 (en) | 2010-03-18 |
| NO20051664L (no) | 2005-05-31 |
| HK1080408A1 (en) | 2006-04-28 |
| EP1549314A1 (en) | 2005-07-06 |
| KR20050056235A (ko) | 2005-06-14 |
| BR0314541A (pt) | 2005-07-26 |
| RU2332218C2 (ru) | 2008-08-27 |
| DE60318081T2 (de) | 2008-11-06 |
| JP2006504741A (ja) | 2006-02-09 |
| CA2501348A1 (en) | 2004-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1594833T1 (sl) | Derivati 1-fenilalkankarboksilne kisline za zdravljenje nevrodegenerativnih bolezni | |
| GEP20084447B (en) | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | |
| MXPA05002420A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos. | |
| GB0223038D0 (en) | Therapeutic compounds | |
| EP1765388B8 (de) | Kombinationstherapie zur vorbeugung oder behandlung der alzheimerschen erkrankung sowie set hierfür | |
| GB2463833A (en) | Methods and compositions for the treatment of neurological disorders | |
| ZA200802897B (en) | New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of Alzheimer's Disease | |
| AU2003206413A1 (en) | Substituted amino carboxamides for the treatment of alzheimer's disease | |
| GB0117645D0 (en) | Therapeutic stratergies for prevention and treatment of alzheimers disease | |
| ZA200606834B (en) | 1-Aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with Alzheimer's disease | |
| WO2004026258A3 (en) | Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson’s disease | |
| AU2003254146A1 (en) | Methods for the treatment of parkinson's disease | |
| AU2003303141A1 (en) | Hydroxypropyl amides for the treatment of alzheimer's disease | |
| GB0504103D0 (en) | Novel method | |
| BR0314541A (pt) | Tratamento de demência e doença de parkinson | |
| PL376346A1 (en) | Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of neurodegeneration | |
| ZA200700945B (en) | Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases | |
| WO2008109521A3 (en) | Method of treatment using atranorin | |
| WO2005012490A3 (en) | Neuroprotective effects of atf6 | |
| WO2003000269A3 (de) | Neue verwendung für pde 10a-inhibitoren | |
| WO2007048034A3 (en) | Use of androgens for the treatment of parkinson' s disease | |
| HK40111000A (en) | Methods for treating alzheimer's disease | |
| WO2004091522A3 (en) | Method for treating neurodegenerative disorders | |
| WO2007017652A3 (en) | Arylakylamines for the treatment of cancer | |
| HK1120037A (en) | New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM9K | Patent not in force due to non-payment of renewal fees |